-
Je něco špatně v tomto záznamu ?
Toxic Megacolon Burdened with COVID-19 Coinfection-Worsening of an Unfavorable Diagnosis: A Single-Center Retrospective Study
T. Řezáč, D. Klos, M. Stašek, R. Vrba, P. Zbořil, P. Špička
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
36294980
DOI
10.3390/life12101545
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: This study primarily sought to evaluate the risk factors for toxic megacolon development and treatment outcomes in Clostridium difficile-positive COVID-19 patients, secondarily to determining predictors of survival. METHODS: During the second COVID-19 wave (May 2020 to May 2021), we identified 645 patients with confirmed COVID-19 infection, including 160 patients with a severe course in the intensive care unit. We selected patients with Clostridium difficile infection (CDI) (31 patients) and patients with toxic megacolon (9 patients) and analyzed possible risk factors. RESULTS: Patients who developed toxic megacolon had a higher incidence (without statistical significance, due to small sample size) of cancer and chronic obstructive pulmonary disease, a higher proportion of them required antibiotic treatment using cephalosporins or penicillins, and there was a higher rate of extracorporeal circulation usage. C-reactive protein (CRP) and interleukin-6 values showed significant differences between the groups (CRP [median 126 mg/L in the non-toxic megacolon cohort and 237 mg/L in the toxic megacolon cohort; p = 0.037] and interleukin-6 [median 252 ng/L in the group without toxic megacolon and 1127 ng/L in those with toxic megacolon; p = 0.016]). As possible predictors of survival, age, presence of chronic venous insufficiency, cardiac disease, mechanical ventilation, and infection with Candida species were significant for increasing the risk of death, while corticosteroid and cephalosporin treatment and current Klebsiella infection decreased this risk. CONCLUSIONS: More than ever, the COVID-19 pandemic required strong up-to-date treatment recommendations to decrease the rate of serious in-hospital complications. Further studies are required to evaluate the interplay between COVID-19 and CDI/toxic megacolon.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031603
- 003
- CZ-PrNML
- 005
- 20230127131233.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/life12101545 $2 doi
- 035 __
- $a (PubMed)36294980
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Řezáč, Tomáš $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic
- 245 10
- $a Toxic Megacolon Burdened with COVID-19 Coinfection-Worsening of an Unfavorable Diagnosis: A Single-Center Retrospective Study / $c T. Řezáč, D. Klos, M. Stašek, R. Vrba, P. Zbořil, P. Špička
- 520 9_
- $a INTRODUCTION: This study primarily sought to evaluate the risk factors for toxic megacolon development and treatment outcomes in Clostridium difficile-positive COVID-19 patients, secondarily to determining predictors of survival. METHODS: During the second COVID-19 wave (May 2020 to May 2021), we identified 645 patients with confirmed COVID-19 infection, including 160 patients with a severe course in the intensive care unit. We selected patients with Clostridium difficile infection (CDI) (31 patients) and patients with toxic megacolon (9 patients) and analyzed possible risk factors. RESULTS: Patients who developed toxic megacolon had a higher incidence (without statistical significance, due to small sample size) of cancer and chronic obstructive pulmonary disease, a higher proportion of them required antibiotic treatment using cephalosporins or penicillins, and there was a higher rate of extracorporeal circulation usage. C-reactive protein (CRP) and interleukin-6 values showed significant differences between the groups (CRP [median 126 mg/L in the non-toxic megacolon cohort and 237 mg/L in the toxic megacolon cohort; p = 0.037] and interleukin-6 [median 252 ng/L in the group without toxic megacolon and 1127 ng/L in those with toxic megacolon; p = 0.016]). As possible predictors of survival, age, presence of chronic venous insufficiency, cardiac disease, mechanical ventilation, and infection with Candida species were significant for increasing the risk of death, while corticosteroid and cephalosporin treatment and current Klebsiella infection decreased this risk. CONCLUSIONS: More than ever, the COVID-19 pandemic required strong up-to-date treatment recommendations to decrease the rate of serious in-hospital complications. Further studies are required to evaluate the interplay between COVID-19 and CDI/toxic megacolon.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Klos, Dušan $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic $1 https://orcid.org/0000000230974418
- 700 1_
- $a Stašek, Martin $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic
- 700 1_
- $a Vrba, Radek $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic
- 700 1_
- $a Zbořil, Pavel $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic
- 700 1_
- $a Špička, Petr $u Department of Surgery I, University Hospital Olomouc, I.P. Pavlova 185/6, 77900 Olomouc, Czech Republic $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 976/3, 77515 Olomouc, Czech Republic $1 https://orcid.org/0000000331662624
- 773 0_
- $w MED00186366 $t Life (Basel, Switzerland) $x 2075-1729 $g Roč. 12, č. 10 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36294980 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131225 $b ABA008
- 999 __
- $a ok $b bmc $g 1889568 $s 1182936
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 12 $c 10 $e 20221005 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
- LZP __
- $a Pubmed-20230119